Listen to this Post
Samsung has long marketed its Galaxy Watch lineup as the ultimate health companion, promising features like ECG readings and blood pressure monitoring. Globally, these features are already live, giving users insight into their cardiovascular health directly from their wrists. However, in the United States, Galaxy Watch owners remain unable to access blood pressure monitoring—a feature that the devices have had hardware for years. The delay has left many wondering why Samsung hasn’t been able to deliver this long-promised capability in one of its most important markets.
Blood pressure monitoring on compatible Galaxy Watches works via the Samsung Health Monitor app, which must be installed both on the watch and a connected smartphone. Users calibrate the app using a medical-grade blood pressure monitor, after which it can track blood pressure readings alongside ECG data. This information feeds into the Samsung Health platform, offering a more comprehensive view of overall health and personalized lifestyle recommendations. Despite this sophisticated system, U.S. users are left at a disadvantage, unable to use this key feature.
The root of the delay isn’t a technological issue—Samsung has had the hardware ready for years. Instead, the bottleneck is regulatory. The U.S. Food and Drug Administration (FDA) must clear any health monitoring feature before it can be offered to consumers. Unlike Samsung’s timelines, the FDA operates on its own schedule, which can be slow and unpredictable. The lack of updates or explanations from Samsung has only fueled frustration among its U.S. user base.
Meanwhile, Apple has managed to launch a similar feature that also required FDA approval. The Apple Watch Series 9, Series 10, Series 11, and Ultra 2 and 3 models now include hypertension detection. Apple’s system isn’t identical—it uses 30-day data trends to flag potential hypertension—but the rollout demonstrates that navigating FDA hurdles is possible. This comparison raises questions: why can Apple succeed while Samsung remains stuck in regulatory limbo, even though Samsung’s hardware has existed longer?
Samsung’s silence has left room for speculation. Did the FDA raise objections? Was there an internal delay in follow-ups? Or is there a deeper technical or regulatory issue? Whatever the reason, U.S. Galaxy Watch users are left waiting, while global users have already benefited from the feature.
What Undercode Says:
Regulatory Bottlenecks Are Real but Manageable
The FDA’s cautious approach to health monitoring technology is understandable, as misreporting blood pressure data could have serious consequences. However, the Apple Watch example shows that these hurdles are navigable. Samsung’s delay suggests either a slower regulatory strategy or insufficient follow-through rather than a technical incapacity.
Market Frustration Could Affect Brand Loyalty
With U.S. customers seeing Apple deliver similar functionality, Samsung risks losing credibility among tech-savvy consumers who value health features. Marketing a product as “health-focused” while key functions remain blocked could backfire, especially with the rise of smartwatches as lifestyle essentials.
Technical Readiness vs. Approval Lag
Samsung’s Galaxy Watch hardware has been capable for years. The discrepancy between global availability and U.S. restrictions highlights a significant gap between product capability and regulatory clearance. Users often equate delayed launches with corporate oversight or incompetence, even if the reality is bureaucratic.
Competitive Pressure Is Mounting
As other brands continue to innovate and secure regulatory approvals, Samsung’s delayed rollout could weaken its competitive edge. Features like blood pressure monitoring are increasingly becoming baseline expectations, not premium extras.
Communication Gap Intensifies User Frustration
The lack of transparency from Samsung compounds the problem. Clearer updates on FDA status or expected timelines could mitigate frustration and demonstrate commitment to U.S. consumers. Silence often leads to speculation, which can harm brand perception more than actual delays.
The Global Perspective Matters
Outside the U.S., the feature is already live, including in markets like Canada. This makes the delay even more glaring, as international users enjoy health insights that U.S. customers can only dream of.
Calibration Requirements Are Understandable
The need for medical-grade calibration is a valid precaution. Accurate blood pressure measurement from a wrist device is complex and necessitates strict calibration protocols. However, U.S. consumers may not see the nuance and instead perceive this as an unnecessary delay.
FDA Hurdles Differ for Each Company
Apple’s workaround—using long-term trend analysis for hypertension detection—demonstrates creative regulatory navigation. Samsung might explore similar alternatives to accelerate the U.S. rollout without compromising accuracy.
Potential Brand Impact
Prolonged absence of this feature could influence purchasing decisions. Users considering Samsung for health tracking might lean toward Apple or other brands that provide immediate functionality, leading to a potential loss in market share.
Innovation vs. Implementation
Samsung’s hardware innovation is evident, but execution lags in critical markets. The story underscores the gap between technological capability and practical deployment in heavily regulated sectors.
Consumer Trust at Stake
Trust is central in health technology. Extended delays without explanation risk undermining confidence in Samsung’s devices, potentially affecting broader brand perception beyond smartwatches.
🔍 Fact Checker Results
✅ Samsung Galaxy Watch blood pressure monitoring works in many countries, but not in the U.S.
✅ Apple Watch hypertension detection cleared by FDA in September 2025 for multiple models.
❌ There’s no public evidence of a hardware issue preventing Samsung’s U.S. launch.
📊 Prediction
Samsung is likely to eventually roll out the blood pressure monitoring feature in the U.S., but timing remains uncertain. They may adopt a phased approach, using a combination of hardware calibration and software trend analysis similar to Apple to gain FDA approval. Meanwhile, the growing competition from Apple and other smartwatch brands may accelerate Samsung’s push to release updates, possibly within the next 12–18 months. User demand and global pressure will likely make this a priority for Samsung’s 2026 roadmap.
🕵️📝✔️Let’s dive deep and fact‑check.
References:
Reported By: www.sammobile.com
Extra Source Hub (Possible Sources for article):
https://www.reddit.com/r/AskReddit
Wikipedia
OpenAi & Undercode AI
Image Source:
Unsplash
Undercode AI DI v2
Bing
🔐JOIN OUR CYBER WORLD [ CVE News • HackMonitor • UndercodeNews ]
📢 Follow UndercodeNews & Stay Tuned:
𝕏 formerly Twitter 🐦 | @ Threads | 🔗 Linkedin | 🦋BlueSky | 🐘Mastodon
